Dr Ingrid Gelissen

MAgSci PhD
Senior Lecturer, Pharmaceutics

A15 - Pharmacy And Bank Building
The University of Sydney

Telephone +61 2 9036 3360

Biographical details

Dr Gelissen initially completed a Masters in Nutrition at Wageningen University, the Netherlands. After working as a research associate for several years overseas and in Sydney, she enrolled in a PhD degree at the Heart Research Institute, the University of Sydney, supported by an NH&MRC scholarship. Since graduating in 2000, she has spent 10 years in cardiovascular research, completing post-doctoral positions at UT Southwestern in Dallas, Texas and the Centre for Vascular Research at the University of New South Wales in Sydney - where she was awarded a prestigious Vice-Chancellors Post-doctoral Fellowship. She joined the Faculty of Pharmacy as a lecturer in 2010.

Research interests

• The role of ABC-lipid transporters in health and disease.

ABC-transporters are membrane proteins involved in the translocation of substrates across cellular membranes. A number of lipid transporters, including ABCA1 and ABCG1, are involved in removing cholesterol from cells, a process that is important in the maintenance of cellular cholesterol homeostasis. Disregulation of cholesterol homeostasis is of interest to a number of diseases including atherosclerosis, which causes cardiovascular disease and neurogenerative diseases. The basic mechanisms by which these transporters operate is poorly understood, as is their post-translational regulation. These aspects are under investigation in our lab.

• The use of cholesterol-lowering mediation in children and adolescents (collaboration with Dr Rebekah Moles and Associate Professor Parisa Aslani).

The statins has been used successfully in adults for the treatment of high plasma cholesterol. Children and adolescents can also have high cholesterol levels, due to genetic factors such as Familial Hypercholesterolemia (FH), lifestyle factors such as obesity or medication use. There are currently no guidelines available for the use of statins in children and adolescents other than those with FH. We are currently performing audits in children’s hospitals in Australia in order to get a better understanding of the use of statins in the paediatric setting.

Keywords

Cardiovascular diseases; Molecular biology; Cell biology; Lipid metabolism; Atherosclerosis

Selected grants

2011

  • The use of Statins in Children - an audit of prescribing data from Australian Children's Hospitals; Moles R, Gelissen I, Aslani P; Society of Hospital Pharmacists of Australia/Research and Development Grants Program.
  • Control of expression and activity of the ABCG1 cholesterol transporter in vascular cells; Gelissen I, Brown A, Brown A; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Burns, V., Sharpe, L., Gelissen, I., Brown, A. (2013). Species variation in ABCG1 isoform expression: Implications for the use of animal models in elucidating ABCG1 function. Atherosclerosis, 226(2), 408-411. [More Information]
  • Luu, W., Sharpe, L., Gelissen, I., Brown, A. (2013). The Role of Signalling in Cellular Cholesterol Homeostasis. IUBMB Life, 65(8), 675-684. [More Information]
  • Gelissen, I., Brown, A. (2012). Predicting response to statins by pharmacogenetic testing. Pharmacogenomics, 13(11), 1223-1225. [More Information]
  • Gelissen, I., Sharpe, L., Sandoval, C., Rao, G., Kockx, M., Kritharides, L., Jessup, W., Brown, A. (2012). Protein kinase A modulates the activity of a major human isoform of ABCG1. Journal of Lipid Research, 53(10), 2133-2140. [More Information]
  • Gelissen, I., Brown, A. (2011). Drug targets beyond HMG-CoA reductase: Why venture beyond the statins? Frontiers in Biology, 6(3), 197-205. [More Information]
  • Kerr, I., Haider, A., Gelissen, I. (2011). The ABCG family of membrane-associated transporters: you don't have to be big to be mighty. British Journal of Pharmacology, 164(7), 1767-1779. [More Information]
  • Calabresi, L., Favari, E., Moleri, E., Adorni, M., Pedrelli, M., Costa, S., Jessup, W., Gelissen, I., Kovanen, P., Bernini, F., et al (2009). Functional LCAT is not required for macrophage cholesterol efflux to human serum. Atherosclerosis, 204, 141-146. [More Information]
  • Out, R., Jessup, W., Le Goff, W., Hoekstra, M., Gelissen, I., Zhao, Y., Kritharides, L., Chimini, G., Kuiper, J., Chapman, M., et al (2008). Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporter A1 and G1. Circulation Research, 102, 113-120. [More Information]
  • Wong, J., Quinn, C., Gelissen, I., Jessup, W., Brown, A. (2008). The effect of statins on ABCA1 and ABCG1 expression in human macrophages is influenced by cellular cholesterol levels and extent of differentiation. Atherosclerosis, 196(1), 180-189. [More Information]
  • Wong, J., Quinn, C., Gelissen, I., Brown, A. (2007). Endogenous 24(S),25-Epoxycholesterol Fine-tunes Acute Control of Cellular Cholesterol Homeostasis. Journal of Biological Chemistry, 283, 700-707.
  • Kim, W., Rahmanto, A., Kamili, A., Rye, K., Guillemin, G., Gelissen, I., Jessup, W., Hill, A., Garner, B. (2007). Role of ABCG1 and ABCA1 in Regulation of Neuronal Cholesterol Efflux to Apolipoprotein E Discs and Suppression of Amyloid- Peptide Generation. Journal of Biological Chemistry, 282, 2851-2861.
  • Glaros, E., Kim, W., Quinn, C., Wong, J., Gelissen, I., Jessup, W., Garner, B. (2005). Glycosphingolipid accumulation inhibits cholesterol efflux via the ABCA1/apolipoprotein A-I pathway: 1-phenyl-2-decanoylamino-3-morpholino-1-propanol is a novel cholesterol efflux accelerator. Journal of Biological Chemistry, 280, 24515-24523.

Conferences

  • Aslani, P., Tiao, D., Gelissen, I., Moles, R. (2011). A retrospective study on statin use in children and adolescents. Australasian Pharmaceutical Science Association (2011), Unkown: University Of South Australia.
  • Tiao, D., Aslani, P., Gelissen, I., Moles, R. (2011). The use of statins in children with cholesterol disorders. Medicines Management 2011, the 37th Society of Hospital Pharmacists of Australia (SHPA) National Conference.

2013

  • Burns, V., Sharpe, L., Gelissen, I., Brown, A. (2013). Species variation in ABCG1 isoform expression: Implications for the use of animal models in elucidating ABCG1 function. Atherosclerosis, 226(2), 408-411. [More Information]
  • Luu, W., Sharpe, L., Gelissen, I., Brown, A. (2013). The Role of Signalling in Cellular Cholesterol Homeostasis. IUBMB Life, 65(8), 675-684. [More Information]

2012

  • Gelissen, I., Brown, A. (2012). Predicting response to statins by pharmacogenetic testing. Pharmacogenomics, 13(11), 1223-1225. [More Information]
  • Gelissen, I., Sharpe, L., Sandoval, C., Rao, G., Kockx, M., Kritharides, L., Jessup, W., Brown, A. (2012). Protein kinase A modulates the activity of a major human isoform of ABCG1. Journal of Lipid Research, 53(10), 2133-2140. [More Information]

2011

  • Aslani, P., Tiao, D., Gelissen, I., Moles, R. (2011). A retrospective study on statin use in children and adolescents. Australasian Pharmaceutical Science Association (2011), Unkown: University Of South Australia.
  • Gelissen, I., Brown, A. (2011). Drug targets beyond HMG-CoA reductase: Why venture beyond the statins? Frontiers in Biology, 6(3), 197-205. [More Information]
  • Kerr, I., Haider, A., Gelissen, I. (2011). The ABCG family of membrane-associated transporters: you don't have to be big to be mighty. British Journal of Pharmacology, 164(7), 1767-1779. [More Information]
  • Tiao, D., Aslani, P., Gelissen, I., Moles, R. (2011). The use of statins in children with cholesterol disorders. Medicines Management 2011, the 37th Society of Hospital Pharmacists of Australia (SHPA) National Conference.

2009

  • Calabresi, L., Favari, E., Moleri, E., Adorni, M., Pedrelli, M., Costa, S., Jessup, W., Gelissen, I., Kovanen, P., Bernini, F., et al (2009). Functional LCAT is not required for macrophage cholesterol efflux to human serum. Atherosclerosis, 204, 141-146. [More Information]

2008

  • Out, R., Jessup, W., Le Goff, W., Hoekstra, M., Gelissen, I., Zhao, Y., Kritharides, L., Chimini, G., Kuiper, J., Chapman, M., et al (2008). Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporter A1 and G1. Circulation Research, 102, 113-120. [More Information]
  • Wong, J., Quinn, C., Gelissen, I., Jessup, W., Brown, A. (2008). The effect of statins on ABCA1 and ABCG1 expression in human macrophages is influenced by cellular cholesterol levels and extent of differentiation. Atherosclerosis, 196(1), 180-189. [More Information]

2007

  • Wong, J., Quinn, C., Gelissen, I., Brown, A. (2007). Endogenous 24(S),25-Epoxycholesterol Fine-tunes Acute Control of Cellular Cholesterol Homeostasis. Journal of Biological Chemistry, 283, 700-707.
  • Kim, W., Rahmanto, A., Kamili, A., Rye, K., Guillemin, G., Gelissen, I., Jessup, W., Hill, A., Garner, B. (2007). Role of ABCG1 and ABCA1 in Regulation of Neuronal Cholesterol Efflux to Apolipoprotein E Discs and Suppression of Amyloid- Peptide Generation. Journal of Biological Chemistry, 282, 2851-2861.

2005

  • Glaros, E., Kim, W., Quinn, C., Wong, J., Gelissen, I., Jessup, W., Garner, B. (2005). Glycosphingolipid accumulation inhibits cholesterol efflux via the ABCA1/apolipoprotein A-I pathway: 1-phenyl-2-decanoylamino-3-morpholino-1-propanol is a novel cholesterol efflux accelerator. Journal of Biological Chemistry, 280, 24515-24523.

For support on your academic profile contact .